Ovoca Bio PLC - Publication of Admission Document
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN OVOCA BIO PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF OVOCA BIO PLC.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC LAW IN THE
Ovoca Bio plc (to be renamed Talisman Metals plc on Admission)
("Ovoca", "Talisman" or the "Company")
Proposed acquisition of up to 100 per cent. of Tadeen International Limited
Change of name to Talisman Metals plc
Fundraising, Share Capital Reorganisation
Admission of the Enlarged Group to trading on AIM
Notice of Extraordinary General Meeting
and
Publication of Admission Document
Ovoca Bio plc (to be renamed Talisman Metals plc on Admission) is pleased to announce that, further to the announcement of
At the same time as the acquisition announcement, Ovoca announced that it had sold its wholly-owned subsidiary Silver Star, which owned 100% of IVIX LLC, thereby, given the Board's recent decision to allow the Orenetide and related patents to lapse, completely exiting the biopharmaceutical business, which had been its core business. The Company therefore, in ceasing any of its former biopharmaceutical development activities and retaining no biopharmaceutical intellectual property, became an AIM Rule 15 cash shell on that date.
The Proposed Acquisition constitutes a reverse takeover under the AIM Rules for Companies (the "AIM Rules") as, inter alia, the Proposed Acquisition will fundamentally change the Company into an operating mining exploration business and therefore, in accordance with Rule 14 of the AIM Rules, application will be made for the enlarged share capital to be readmitted to AIM.
Tadeen is a
The nature of the Company's business will be transformed by the Transaction and, in order to reflect its new activities, it is proposed to change the Company's name to Talisman Metals plc, subject to the approval of the Shareholders and Irish Companies Registration Office ("CRO").
In connection with the Proposed Acquisition the Company will be issuing Consideration Shares, Novation Shares, Tadeen Creditor Shares and Fundraising Shares. Additionally, the Company is proposing a 3:1 consolidation whereby every 3 Existing Ordinary Shares will be exchanged for 1 New Ordinary Share, resulting in a nominal value of New Ordinary Shares of
At the same time, the Company has completed the Fundraising to raise a gross amount of
In the opinion of the Existing Directors, the acquisition of Tadeen is an attractive opportunity for the Company. The development of promising mineral properties, focused on Copper, a commodity that enjoys strong future growth fundamentals, in a country that is well endowed geologically and has a strong, and investor-friendly legal framework for mineral development activities. Provides an attractive opportunity that the Existing Directors believe, has the potential to generate significant shareholder value.
Upon completion of the Proposed Transaction, the Company will trade under the new name of "Talisman Metals plc" and its new TIDM will be "TLM".
Beaumont Cornish Limited ("Beaumont Cornish") is the Nominated Adviser and CMC Markets UK plc is acting as Broker to the Company.
The Admission Document is being posted to Shareholder and will shortly be available on the Company's website at https://ovocabio.com. Trading in the Company's Ordinary Shares on AIM remains suspended pending approval by Shareholders at the EGM for the Transaction.
Ovoca Bio has published an Admission Document in order to seek shareholder approval for the Proposed Acquisition and associated resolutions. Extracts from the Admission Document including a Timetable and Placing Statistics are included as an Appendix to this announcement. At the same time the Company has published a Notice of EGM to be held at The Mespil Hotel,
"I want to congratulate the entire team of employees, counterparties, consultants and advisors on getting this transaction through the process of readmission to AIM.
Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Admission Document. Shareholders are strongly encouraged to read the Admission Document in full as part of their voting consideration at the General Meeting.
For the purposes of
Enquiries:
|
Ovoca Bio plc Timothy McCutcheon, CEO |
Tel: +353 1 661 9819 |
|
Nominated Adviser Beaumont Cornish Limited |
Tel: +44 (0) 20 7628 3396 |
|
Broker CMC Markets UK plc Thomas Smith /
|
Tel: +44 (0) 20 3003 8255 |
Beaumont Cornish, which is authorised and regulated in the
CMC Markets UK plc ("CMC"), which is authorised and regulated in the
No representation or warranty, express or implied, is made by Beaumont Cornish, CMC or any of their respective Representatives as to the contents of this document (without limiting the statutory rights of any person to whom this document is issued). No liability whatsoever is accepted by Beaumont Cornish, CMC or any of respective Representatives for the accuracy of any information or opinions contained in this document or for the omission of any material information for which it is not responsible. The information contained in this document is not intended to inform or be relied upon by any subsequent purchasers of Ordinary Shares (whether on or off exchange) and accordingly, to the extent permitted by law, no duty of care is accepted by the Company, Beaumont Cornish or CMC} in relation to any of them.
This announcement includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements relate to, inter alia, analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and the Enlarged Group's future prospects, developments and business strategies.
These forward-looking statements can be identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will" or the negative of those variations, or comparable expressions, including references to assumptions. These forward-looking statements are primarily contained in Part I - Letter from the CEO of the Admission Document but may also appear elsewhere throughout it.
The forward-looking statements in the Admission Document, including statements concerning projections of the Enlarged Group's future results, operations, profits and earnings, are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those forward-looking statements.
Certain risks to and uncertainties for the Enlarged Group are specifically described in the risk factors set out in Part 2 - Risk Factors of the Admission Document. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Enlarged Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements.
Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements in this document are based on certain factors and assumptions, including the Directors' current views with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Enlarged Group's operations, results of operations, growth strategy and liquidity. Whilst the Directors consider these assumptions to be reasonable based upon information currently available to them, they may prove to be incorrect. Accordingly, prospective investors are cautioned not to place undue reliance on any forward-looking statements and should specifically consider the risk factors set out in Part II - Risk Factors of the Admission Document that could cause actual results to differ before making an investment decision.
Neither the Directors nor the Company undertake any obligation to update forward-looking statements or risk factors other than as required by the AIM Rules,
Appendix 1
Background and history
In 2023 Tadeen acquired 100% of the issued share capital of Horizons, a Moroccan legal entity that owns the thirteen (13) Exploration Permits, including the 10 Core Exploration Permits, and one (1) non-core mining licence.
The Projects are within central
The Exploration permits
The Company will only focus its work on the Core Exploration Permits, five comprising the Tizert Project and five making up the Argana Project, with a total combined area of 129.8km2. The CPR only describes these two Projects; given no exploration expenditure will be spent on the other permits and
The CPR includes details of the Core Exploration Permits. The first renewal period for all Argana Project Exploration Permits, and the three Exploration Permits within the Tizert Project (namely Tizert North and Tizert South as seen below) expired during
Tizert Project
At the Fougnar and Tizert South permits, the Precambrian-to-Cambrian-aged Adoudou Formation is exposed, unconformably overlying the Precambrian basement. The lower part of the Adoudou Formation is named the 'Basal Series' and is the host to the mineralisation on the Tizert Project and at Managem's important Tizert Deposit (the 'Tizert Deposit'). On Fougnar and Tizert South permits mineralisation is in the form of malachite within greenish siltstones as scattered minor occurrences within two or possibly three stratigraphic levels within the Basal Series which typically has a dip of 15° to 20° to the to the west and SSE respectively.
The target type is Cu-Ag deposits of the Sediment- Hosted-Stratiform Copper (SHSC) type which are the world's second most important in terms of copper production4, typically comprising extensive layers with copper sulphide mineralisation that can reach tens of metres in thickness. The nearby Tizert Deposit owned by Managem is of this type. The southernmost of the Tizert North permits is approximately 8km NE from the northern limit the Tizert Deposit and potentially 'on trend' but the depth to the target Basal Series is over 300m. The Tizert Projects, particularly Fougnar will be the focus of the Issuer's immediate strategy and work programme expenditure.
Argana Project
The Argana Project is in younger rocks of the Triassic aged red-bed formations which were deposited in a late Permian to Triassic rift basins. Copper and lesser Ag and uranium (U) mineralisation is found in the area hosted by 30°-40° (mostly) northward dipping peneconcordant lenses within the middle units of the Triassic red-beds. Lenses are 10-40m in lateral extent, up to 2.5m thick and with unknown down-dip extent, well exposed on the adjacent properties, one of which is within in an excluded block within one of the permits. There are some small-scale mining activities exploiting the lenses on the adjacent properties. The mineralisation type is of the Red-bed copper which is a smaller subtype of the Sediment Hosted Copper type. Sporadic uranium mineralisation is observed at surface but the potential for more significant mineralisation of the sandstone-hosted type should be considered, as the geological setting is favourable, i.e. extensive intra-cratonic rift-controlled continental fluvial to marginal marine sediments, within an area with volcanic and other potential uranium-bearing source rocks.
Exploration work
Horizons ("HM") has not completed any exploration on the Projects, the small amount of documented work was by previous explorers, mostly by the current holding company HM. There has been no drilling except for three holes completed during
Tizert Project
On the Tizert Projects HM has carried out geological mapping, rock and channel sampling, at the Fougnar and Tizert South permits; achieving grades mostly between 0.5 and 1.44 % Cu over intervals with length 0.5m to 1.3m from the channel samples, from mineralisation in the 'Basal Series' which is the host to most of the copper at Managem's Tizert deposit. A single drill-hole on the Tizert South permit was completed in
Argana Project
At the Argana Project, HM carried out rock chip and channel sampling on the permits comprising the Project and on adjacent ground, and enclosed excluded zones (small Exploitation Licenses by other companies within HM's Exploration Permits). HM confirmed that high grade Cu mineralisation (up to 4.75% Cu) with up to 50g/t Ag is present, hosted in lenses found within the enclosed excluded zones (not part of the Project), of the 'Red-bed' Sediment-Hosted copper type. On the permit areas held by HM, some lower grade copper mineralisation has been sampled, the best being a channel sample with 0.88% Cu over 1.0m (true thickness). A surface electrical survey was completed during
Details of the Fundraising
The Company has conditionally raised
Placing
The Company is proposing to issue 4,545,454 New Ordinary Shares at the Placing Price to the Placees to raise
The Placing Agreement is conditional, amongst other things, upon Admission having become effective by no later than
Subscription
The Company is proposing to issue 10,454,546 Subscription Shares at the Issue Price to the Subscribers to raise
Each Subscription Agreement is conditional, amongst other things, upon Admission having become effective by no later than
Further details of the Subscription Agreements are set out in paragraph 13(e) of Part 8 (Additional Information, Material Contracts) of the Document.
The Placing Shares and Subscription Shares will represent approximately 23.4 per cent. of the Enlarged Share Capital.
Use of Proceeds
The Company has conditionally raised Gross Proceeds of
- To settle outstanding Admission expenses of approximately
- To fund the Phase 1 Exploration Program amounting to
- To fund approximately 75% of Phase 2 Exploration Expenditure of approximately
- General Working Capital purposes of approximately
Shareholder approval
Ovoca Bio has published an Admission Document in order to seek shareholder approval for the Proposed Acquisition and associated resolutions.
Extraordinary General Meeting and Resolutions
Set out at the end of this Document is the Notice convening the Extraordinary General Meeting to be held at
• Resolution 1, which will be proposed as an ordinary resolution, is to approve the Acquisition for the purposes of Rule 14 of the AIM Rules, subject to the passing of Resolutions 1 above and 3 and 4 below;
• Resolution 2, which will be proposed as an ordinary resolution, is to approve the consolidation of the Company's Existing Ordinary Shares into Ordinary Shares of
• Resolution 3, which will be proposed as an ordinary resolution, is to approve, subject to the passing of Resolution 2 above, with effect from 23.59 hours on the date of passing of this resolution, all of the ordinary shares of
• Resolution 4, which will be proposed as an ordinary resolution, is to approve, subject to the passing of resolution 2 and 4 above, the increase in the authorised share capital to
• Resolution 5, which will be proposed as a special resolution, is to approve, subject to the passing of resolution 1 above, the change of the main objects clause of the Company, which will remove all references to all biotech projects;
• Resolution 6, which will be proposed as a special resolution, is to approve, subject to the passing of resolution 2, 3 and 4 above, proposed changes to the Memorandum of Association to reflect the changes to the share capital as set out above;
• Resolution 7, which will be proposed as a special resolution, is to approve, subject to the passing of resolutions 2,3 and 4 above, the adoption of new Articles, including setting out the new share capital of the Company and the rights attaching to the of the Deferred Shares;
• Resolution 8, which will be proposed as a special resolution, is to approve, subject to the passing of resolution 1 above, and the approval of the Registrar of Companies, the change of the name of the Company to Talisman Metals plc; and
• Resolution 9, which will be proposed as a special resolution, is to approve, subject to the passing of resolution 1 and 8 above, proposed changes to the Memorandum of Association to reflect the new name and proposed changes to the Articles of Association to reflect the new name.
Appendix 2
Share Capital and Placing Statistics
|
Issue Price (per Fundraising Share) |
7.7p |
|
Number of Existing Ordinary Shares as at the date of this Document |
88,458,805 |
|
Number of New Ordinary Shares in issue following the Share Consolidation |
29,486,268 |
|
Number of Consideration Shares, Novation Shares and Tadeen Creditor Shares being issued |
19,688,650 |
|
Number of Placing Shares being issued |
4,545,454 |
|
Number of Subscription Shares being issued |
10,454,546 |
|
Enlarged Issued Share Capital on Admission |
64,174,918 |
|
Fundraising Shares as a percentage of the Enlarged Share Capital |
23.4% |
|
Number of Director Options |
3,100,000 |
|
Number of BCL Warrants |
1,298,701 |
|
Number of Broker Warrants and Introducer Warrants |
392,727 |
|
Number of Introducer Warrants |
120,000 |
|
Fully Dilutive Ordinary Share Capital Admission |
68,693,619 |
|
Total Dilutive Instruments as a percentage of the fully diluted basis on Admission capital on Admission |
7.0% |
|
Market capitalisation of the Company at the Issue Price following Admission(1) |
£4.9 million |
|
Gross proceeds of the Fundraising receivable by the Company |
£1.155 million |
|
Estimated Net Proceeds of the Fundraising receivable by the Company(2) |
£0.630 million |
|
|
|
|
AIM ticker on Admission |
TLM |
|
ISIN for Existing Ordinary Shares |
IE00B4XVDC01 |
|
ISIN in respect of the New Ordinary Shares |
IE000XRZAWV1 |
SEDOL BPVD4J9
LEI 213800ST2AK5XQ1O5207
Notes:
(1) The market capitalisation of the Group at any given time will depend on the market price of the Shares at that time, but this calculation is based upon the Issue Price.
(2) After deduction of estimated commissions, fees and expenses payable by the Company of approximately
Appendix 3
Expected Timetable
|
Publication of this Admission Document
|
|
|
Latest time and date for receipt of Forms of Proxy for the Extraordinary General Meeting
|
|
|
Extraordinary General Meeting |
|
|
Record Date for the Share Consolidation (the "Record Date")
|
|
|
Expected time and date of cancellation of trading on AIM of the Existing Ordinary Shares
|
|
|
Expected time and date of Admission, issue of the New Ordinary Shares and commencement of dealings in the Enlarged Share Capital on AIM
|
8.00 a.m
|
|
(i) Or if later, as soon as practicable after the Annual General Meeting convened for
|
|
|
Note: Each of the dates in the above timetable are subject to change without further notice at the discretion of the Company and the Nomad. All times are UK times unless otherwise stated.
|
|
Appendix 4
Set out below is the unaudited pro forma statement of net assets of the Enlarged Group as at
• the acquisition of Tadeen by Ovoca on 30 June 2025;
• the issue of the Placing Shares and Subscription Shares; and
• the settlement of the costs associated
on the net assets of Ovoca as if the acquisition of Tadeen, the Placing and [the Subscription] had taken place on
The Pro Forma Financial Information has been prepared for illustrative purposes only and, because of its nature, will not represent the actual financial position of the Enlarged Group as if the acquisition had taken place on
|
|
(Unaudited) Ovoca as at (Note 1) |
(Unaudited) Tadeen as at (Note 2) |
Adjustment for the net proceeds from the Placing and Subscription (Note 3) |
Adjustment for the forgiveness of liabilities of Tadeen on the acquisition by Ovoca |
Pro forma net assets |
|
|
€'000 |
€'000 |
€'000 |
€'000 |
€'000 |
|
ASSETS |
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
|
Available for sale financial assets |
96 |
- |
- |
- |
96 |
|
Exploration asset - |
- |
478 |
- |
- |
478 |
|
|
96 |
478 |
- |
- |
574 |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
Trade and other receivables |
39 |
- |
- |
- |
39 |
|
Cash and cash equivalents |
1,526 |
54 |
725 |
- |
2,305 |
|
|
|
|
|
|
|
|
TOTAL ASSETS |
1,661 |
532 |
725 |
- |
2918 |
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
Trade and other payables |
(186) |
(321) |
- |
296 |
(211) |
|
Provisions |
- |
(2) |
- |
- |
(2) |
|
|
(186) |
(323) |
- |
296 |
(213) |
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
Liabilities included in disposal group classified as held for sale |
(210) |
- |
- |
- |
(210) |
|
|
|
|
|
|
|
|
TOTAL LIABILITIES |
(396) |
(323) |
- |
296 |
(423) |
|
|
|
|
|
|
|
|
NET ASSETS |
1,265 |
209 |
725 |
296 |
2,495 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
1. The financial information of Ovoca Bio PLC ("Ovoca") as at
2. The financial information of Tadeen International Limited and its subsidiaries ("Tadeen") has been extracted from the unaudited interim consolidated financial information of Tadeen as set out in Part 5 of this document.
3. The adjustment represents expected gross proceeds of
a. €/$ = 1.15
b. £/€ = 1.14
4. On execution of the share purchase agreement to acquire Tadeen, the loans from the shareholders of Tadeen will be forgiven in exchange for non-cash consideration.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE